AU1395999A - Methods for the use of inhibitors of co-repressors for the treatment of neoplastic diseases - Google Patents

Methods for the use of inhibitors of co-repressors for the treatment of neoplastic diseases Download PDF

Info

Publication number
AU1395999A
AU1395999A AU13959/99A AU1395999A AU1395999A AU 1395999 A AU1395999 A AU 1395999A AU 13959/99 A AU13959/99 A AU 13959/99A AU 1395999 A AU1395999 A AU 1395999A AU 1395999 A AU1395999 A AU 1395999A
Authority
AU
Australia
Prior art keywords
repressor
fusion protein
steroid
operatively associated
smrt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU13959/99A
Other languages
English (en)
Inventor
Ronald M Evans
Richard J. Lin
Laszlo Nagy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Salk Institute for Biological Studies
Original Assignee
Salk Institute for Biological Studies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/966,876 external-priority patent/US6706762B1/en
Application filed by Salk Institute for Biological Studies filed Critical Salk Institute for Biological Studies
Publication of AU1395999A publication Critical patent/AU1395999A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU13959/99A 1997-11-10 1998-11-10 Methods for the use of inhibitors of co-repressors for the treatment of neoplastic diseases Abandoned AU1395999A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/966,876 US6706762B1 (en) 1997-05-01 1997-11-10 Methods for the use of inhibitors of co-repressors for the treatment of neoplastic diseases
US08966876 1997-11-10
PCT/US1998/023962 WO1999023885A1 (en) 1997-11-10 1998-11-10 Methods for the use of inhibitors of co-repressors for the treatment of neoplastic diseases

Publications (1)

Publication Number Publication Date
AU1395999A true AU1395999A (en) 1999-05-31

Family

ID=25511984

Family Applications (1)

Application Number Title Priority Date Filing Date
AU13959/99A Abandoned AU1395999A (en) 1997-11-10 1998-11-10 Methods for the use of inhibitors of co-repressors for the treatment of neoplastic diseases

Country Status (4)

Country Link
EP (1) EP1037533A1 (de)
AU (1) AU1395999A (de)
CA (1) CA2308377A1 (de)
WO (1) WO1999023885A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9915126D0 (en) * 1999-06-30 1999-09-01 Imp College Innovations Ltd Control of gene expression
GB0005199D0 (en) * 2000-03-04 2000-04-26 Imp College Innovations Ltd Modulation of histone deacetylase
US7473555B2 (en) 2000-04-27 2009-01-06 Geron Corporation Protocols for making hepatocytes from embryonic stem cells
US7256042B2 (en) 2000-04-27 2007-08-14 Geron Corporation Process for making hepatocytes from pluripotent stem cells
US6458589B1 (en) 2000-04-27 2002-10-01 Geron Corporation Hepatocyte lineage cells derived from pluripotent stem cells
US7282366B2 (en) 2000-04-27 2007-10-16 Geron Corporation Hepatocytes for therapy and drug screening made from embryonic stem cells
EP1170008A1 (de) * 2000-07-07 2002-01-09 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Valproinsäure und dessen Derivate als Inhibitoren der Histone deacetylase
GB0124391D0 (en) * 2001-10-11 2001-11-28 Gene Expression Technologies L Control of gene expression
AU2002348474A1 (en) 2001-10-18 2003-04-28 The Salk Institute For Biological Studies Methods of using deacetylase inhibitors to promote cell differentiation and regeneration
AU2003262788A1 (en) * 2002-08-23 2004-03-11 Sangamo Biosciences, Inc. High-throughput screen for modulators of chromatin modifying activity
FR2858932B1 (fr) * 2003-08-22 2009-10-30 Oreal Composition destinee a lutter contre la degradation des fibres de collagene induite en condition d'exposition solaire naturelle
US7507552B1 (en) 2004-04-16 2009-03-24 Takeda San Diego, Inc. Crystallization of histone deacetylase 2
BRPI0613429A2 (pt) 2005-07-14 2009-02-10 Takeda San Diego Inc inibidores de histona desacetilase
WO2007100795A2 (en) * 2006-02-27 2007-09-07 Gilead Colorado, Inc. Combinations comprising a histone deacetylase inhibiting agent and a nuclear hormone receptor ligand for treating cardiovascular conditions
GB2453074B (en) 2006-06-02 2011-06-22 Geron Corp Differentiation of primate pluripotent cells to hepatocyte-lineage cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091518A (en) * 1989-11-16 1992-02-25 The Salk Institute For Biological Studies Beta retinoic acid response elements compositions and assays
US6777217B1 (en) * 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto

Also Published As

Publication number Publication date
EP1037533A1 (de) 2000-09-27
WO1999023885A1 (en) 1999-05-20
CA2308377A1 (en) 1999-05-20

Similar Documents

Publication Publication Date Title
US6706762B1 (en) Methods for the use of inhibitors of co-repressors for the treatment of neoplastic diseases
Nagy et al. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase
Jansen et al. Multimeric complexes of the PML-retinoic acid receptor alpha fusion protein in acute promyelocytic leukemia cells and interference with retinoid and peroxisome-proliferator signaling pathways.
Collingwood et al. Spectrum of transcriptional, dimerization, and dominant negative properties of twenty different mutant thyroid hormone beta-receptors in thyroid hormone resistance syndrome.
AU1395999A (en) Methods for the use of inhibitors of co-repressors for the treatment of neoplastic diseases
Leng et al. Ligand-dependent conformational changes in thyroid hormone and retinoic acid receptors are potentially enhanced by heterodimerization with retinoic X receptor
US6184353B1 (en) Method for modulating processes mediated by farnesoid activated receptors
US20030044888A1 (en) Novel steroid-activated nuclear receptors and uses therefor
US5747661A (en) Retinoid-inducible response elements
Tate et al. Distinct binding determinants for 9-cis retinoic acid are located within AF-2 of retinoic acid receptor α
Hauksdóttir et al. DNA recognition by the aberrant retinoic acid receptors implicated in human acute promyelocytic leukemia
WO1996021726A9 (en) Identification of a distinct retinoid-responsive pathway and uses therefor
US6893830B1 (en) Method of screening oxysterol activation of LXRα
CA2194169A1 (en) Mammalian peroxisome proliferator-activated receptors and uses thereof
CA2222562A1 (en) Method for screening for receptor agonists and antagonists
US6268173B1 (en) Polynucleotide encoding transcriptional intermediary factor-2
Lammi et al. Corepressor interaction differentiates the permissive and non-permissive retinoid X receptor heterodimers
Claret et al. A shift in the ligand responsiveness of thyroid hormone receptor α induced by heterodimerization with retinoid X receptor α
WO1993013129A1 (en) Novel rxr-containing heterodimers and method of use
Pemrick et al. Characterization of the chimeric retinoic acid receptor RARα/VDR
US7132258B1 (en) Nucleic acid encoding vitamin D receptor related polypeptide
Halachmi Characterization and cloning of an estrogen receptor coactivator
DEJEAN Multimeric complexesof the PML-retinoic acid receptor fusion protein in acute promyelocytic leukemia cells and interference with retinoid and peroxisome-proliferator signaling pathways
Benkő Molecular Determinants of Co-regulator Binding and Transcriptional Activity of the Retinoic Acid Receptor–Retinoid X Receptor Heterodimer
Hauksdóttir Retinoic acid receptors: The effects of differences in DNA recognition and corepressor binding on transcriptional regulation

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted